Medicare Coverage for Hepatitis C: 2025 Guide
Hepatitis C (HCV) is a curable disease. Modern direct-acting antiviral (DAA) medications cure more than 95% of HCV infections in 8–12 weeks — one of the most remarkable achievements in modern medicine. Medicare Part D covers these curative medications, and the 2025 $2,000 out-of-pocket cap has eliminated the financial barrier that previously kept many Medicare beneficiaries from accessing treatment.
Hepatitis C Coverage Quick Reference
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| HCV antibody screening | Part B (preventive) | $0 — free | Adults born 1945–1965; others at increased risk; once per lifetime + as needed |
| HCV RNA (viral load) testing | Part B | 20% after $257 deductible | For diagnosis confirmation and treatment monitoring |
| HCV genotype testing | Part B | 20% after deductible | Determines which DAA regimen to use (less important with pangenotypic agents) |
| Liver function tests (ALT, AST, bilirubin) | Part B | 20% after deductible | Baseline and monitoring during treatment |
| FibroScan / liver elastography | Part B | 20% after deductible | Non-invasive fibrosis staging; covered when medically necessary |
| Liver biopsy | Part B or Part A | 20% or A deductible | For fibrosis staging when non-invasive tests inconclusive |
| Ledipasvir/sofosbuvir (Harvoni) | Part D | Up to $2,000 OOP cap | Genotypes 1, 4, 5, 6; 8–12 weeks; list price ~$20,000–$35,000/course |
| Sofosbuvir/velpatasvir (Epclusa) | Part D | Up to $2,000 OOP cap | Pangenotypic (all genotypes); 12 weeks; widely used |
| Glecaprevir/pibrentasvir (Mavyret) | Part D | Up to $2,000 OOP cap | Pangenotypic; 8 weeks for most treatment-naive patients; shortest course |
| Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) | Part D | Up to $2,000 OOP cap | For treatment-experienced patients or retreatment |
| Gastroenterologist / hepatologist visits | Part B | 20% after deductible | HCV specialist management |
| Liver ultrasound (cirrhosis monitoring) | Part B | 20% after deductible | Every 6 months for cirrhotic patients (liver cancer surveillance) |
| AFP (alpha-fetoprotein) lab test | Part B | 20% after deductible | Liver cancer surveillance in cirrhotic patients |
| Upper endoscopy (varices screening) | Part B | 20% after deductible | For esophageal varices in cirrhotic patients |
| Beta blockers (variceal prophylaxis) | Part D | Tier 1 generic; very low cost | Propranolol, nadolol for variceal bleeding prevention |
| Lactulose, rifaximin (hepatic encephalopathy) | Part D | Varies; rifaximin Tier 3–4 | For HCV-related cirrhosis complications |
| Liver transplant | Part A | $1,676 deductible | For end-stage liver disease from HCV cirrhosis |
Free HCV Screening: Who Qualifies
Medicare Part B covers hepatitis C screening at $0 cost (no copay, no deductible) for:
- Adults born between 1945 and 1965 — once in a lifetime (baby boomers have HCV prevalence ~3.5x the general population due to transmission before blood supply screening began in 1992)
- Adults at increased risk at any age — people who currently inject drugs, or who have ever injected drugs; recipients of blood products or organ transplants before 1992; people with HIV; people on hemodialysis; others as determined by their physician
- If you have a positive screening result, follow-up testing (HCV RNA confirmation) is covered under Part B at 20% coinsurance
DAA Medications: Cures That Medicare Now Makes Affordable
Direct-acting antiviral (DAA) medications for hepatitis C represent one of the most dramatic therapeutic advances in medicine — achieving sustained virologic response (SVR, effectively a cure) in over 95% of patients with 8–12 weeks of oral treatment. However, these drugs have historically been expensive:
- Mavyret (8-week course): approximately $20,000–$25,000 list price
- Epclusa (12-week course): approximately $25,000–$35,000 list price
- Harvoni (12-week course): approximately $25,000–$40,000 list price
Before 2025, a Medicare beneficiary in the catastrophic phase could pay $5% of these costs — potentially $1,500–$2,000+ per treatment course. The 2025 $2,000 annual Part D OOP cap means:
- Your maximum annual drug spending is $2,000 regardless of drug cost
- If your HCV treatment course costs $25,000, your OOP is capped at $2,000
- The Medicare Prescription Payment Plan can spread that $2,000 over monthly installments
Prior authorization is required for most DAA prescriptions. Your gastroenterologist or hepatologist will submit the required documentation.
Pangenotypic Regimens: Simplified Treatment
Modern DAA therapy has been simplified by pangenotypic regimens that work across all hepatitis C genotypes, eliminating the need for genotype testing before starting treatment:
- Mavyret (glecaprevir/pibrentasvir): 8 weeks for most treatment-naive patients without cirrhosis; pangenotypic; the shortest available course
- Epclusa (sofosbuvir/velpatasvir): 12 weeks; pangenotypic; widely used; slightly longer course than Mavyret
Both are covered under Part D. The choice between them depends on individual patient factors, prior treatment history, presence of cirrhosis, and other medications.
After Cure: Ongoing Monitoring for Cirrhosis Patients
Achieving SVR (cure) with DAA therapy does not eliminate the need for ongoing monitoring in patients who had cirrhosis at the time of treatment. Cirrhosis persists even after the virus is eliminated, and cirrhotic patients remain at elevated risk for hepatocellular carcinoma (liver cancer). Medicare covers:
- Liver ultrasound every 6 months (liver cancer surveillance) — Part B at 20%
- Alpha-fetoprotein (AFP) blood test — Part B at 20%
- Upper endoscopy for esophageal varices — Part B at 20%
- Ongoing hepatology or gastroenterology follow-up — Part B at 20%
Patients who achieved SVR without cirrhosis have a dramatically reduced risk of liver cancer and generally do not need routine surveillance imaging — confirm with your specialist.
Frequently Asked Questions
Yes. Medicare Part D covers all FDA-approved direct-acting antiviral (DAA) medications for hepatitis C, including Mavyret, Epclusa, Harvoni, and Vosevi. These drugs cure more than 95% of HCV infections in 8–12 weeks. Starting in 2025, the Part D out-of-pocket cap is $2,000/year — meaning your maximum cost for a $20,000–$35,000 DAA treatment course is $2,000. Prior authorization is typically required. Work with your gastroenterologist or hepatologist to submit the documentation needed for coverage approval.
Yes, at no cost for qualifying patients. Medicare Part B covers hepatitis C antibody screening at $0 — free — for adults born between 1945 and 1965, and for younger adults at increased risk (people who inject drugs, HIV-positive individuals, pre-1992 blood product recipients). If the screening is positive, confirmatory HCV RNA testing is covered under Part B at 20% coinsurance. If you've never been tested and you're in the baby boomer generation, ask your doctor for a free HCV screen at your next visit.
Yes. Patients with cirrhosis can still be treated with DAA medications — though some regimens require longer treatment courses (12 weeks rather than 8 for Mavyret) or additional ribavirin. Medicare Part D covers DAA therapy regardless of fibrosis stage. After successful treatment, cirrhotic patients remain at elevated risk for liver cancer and need ongoing surveillance — liver ultrasound every 6 months and AFP blood test — both covered under Part B at 20% coinsurance.